Roche drug fails Phase III schizophrenia trials
This article was originally published in Scrip
Executive Summary
Bitopertin, Roche's experimental drug for schizophrenia, has failed the first two of six Phase III trials.
You may also be interested in...
Finance Watch: Prepare For September IPOs To Rebound From August Slowdown
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
Q3 Review: Editor’s Picks Of Scrip's Top Stories
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.